Abstract
The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.
Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.
Current Topics in Medicinal Chemistry
Title:Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Volume: 17 Issue: 12
Author(s): Jerzy Leszek, Elzbieta Trypka, Vadim V. Tarasov, Ghulam Md Ashraf and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.
Abstract: The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.
Export Options
About this article
Cite this article as:
Leszek Jerzy, Trypka Elzbieta, Tarasov V. Vadim, Ashraf Md Ghulam and Aliev Gjumrakch, Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease, Current Topics in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1568026617666170103163403
DOI https://dx.doi.org/10.2174/1568026617666170103163403 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Current Treatment and Drug Discovery Against Leishmania spp. and Plasmodium spp.: A Review
Current Drug Targets Genetic Association Studies: An Information Content Perspective
Current Genomics Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Calcifediol – More than the Stepchild of CKD-MBD Therapy?
Current Vascular Pharmacology Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Current Drug Targets Electrospun Nanofibers for Diabetes: Tissue Engineering and Cell-Based Therapies
Current Stem Cell Research & Therapy Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity?
Current Aging Science Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress
Current Neurovascular Research Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design RAGE and its Ligands in Retinal Disease
Current Molecular Medicine A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Treatment of Atopic Dermatitis: Current Status and Future Prospects
Current Drug Therapy Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study
Current Alzheimer Research Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry